FOLH1 and prostate carcinoma: Following the introduction of PSMA PET ligands, PSMA PET imaging has evolved to the backbone of the recurrence work-up in the context of biochemical recurrence (BCR) of prostate cancer with elevated tumour marker levels (prostate-specific antigen, PSA).